Liminatus Pharma LLC(LIMN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LIMN Liminatus Pharma LLC

休市中 07-31 16:00:00 EDT

0.1030

+0.0009

+0.88%

盘后0.1018

-0.0012-1.17%

19:59 EDT

最高0.1056	最低0.0983	成交量463.46万
今开0.1030	昨收0.1021	日振幅7.15%
总市值691.75万	流通市值299.44万	总股本6,716万
成交额48.70万	换手率15.94%	流通股本2,907万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LIMN","market":"US","secType":"STK","nameCN":"Liminatus Pharma LLC","latestPrice":0.103,"timestamp":1785528000000,"preClose":0.1021,"halted":0,"volume":4634553,"hourTrading":{"tag":"盘后","latestPrice":0.1018,"preClose":0.103,"latestTime":"19:59 EDT","volume":70205,"amount":7157.3158,"timestamp":1785542374702,"change":-0.0012,"changeRate":-0.01165,"amplitude":0.035922},"delay":0,"changeRate":0.008814887365328091,"floatShares":29071600,"shares":67160400,"eps":-0.387713,"marketStatus":"休市中","change":0.0009,"latestTime":"07-31 16:00:00 EDT","open":0.103,"high":0.1056,"low":0.0983,"amount":486964.57989333,"amplitude":0.071499,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.387713,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.1021,"preHourTrading":{"tag":"盘前","latestPrice":0.1016,"preClose":0.1021,"latestTime":"09:27 EDT","volume":1391712,"amount":150044.89636416,"timestamp":1785504421984,"change":-0.0005,"changeRate":-0.004897,"amplitude":0.227228},"postHourTrading":{"tag":"盘后","latestPrice":0.1018,"preClose":0.103,"latestTime":"19:59 EDT","volume":70205,"amount":7157.3158,"timestamp":1785542374702,"change":-0.0012,"changeRate":-0.01165,"amplitude":0.035922},"volumeRatio":1.8989277213681468},"requestUrl":"/m/hq/s/LIMN/tweets","defaultTab":"tweets","newsList":[{"id":"1167262674","title":"利米纳图斯制药修订与Innocsai最终合并协议 以拓展肿瘤细胞疗法产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=1167262674","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167262674?lang=zh_cn&edition=full","pubTime":"2026-07-01 04:31","pubTimestamp":1782851507,"startTime":"0","endTime":"0","summary":"利米纳图斯制药已修订其与Innocsai公司的最终合并协议，此举旨在进一步拓展其在肿瘤细胞疗法领域的研发管线。此次协议的调整将为公司在该关键治疗领域的发展提供新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175907493","title":"利米纳图斯制药公司 - Innocsai成员将从特定战略交易中获得未来净收益的20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175907493","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175907493?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:05","pubTimestamp":1779365124,"startTime":"0","endTime":"0","summary":"利米纳图斯制药公司宣布，Innocsai成员将有权从公司未来达成的特定战略交易中，获得净收益的20%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101364959","title":"Liminatus Pharma公司 - 据SEC文件，Innocsai成员将获16亿股，每股0.20美元，外加20%或然价值权","url":"https://stock-news.laohu8.com/highlight/detail?id=1101364959","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101364959?lang=zh_cn&edition=full","pubTime":"2026-05-21 05:06","pubTimestamp":1779311181,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，Liminatus Pharma公司的股东——Innocsai成员，将获得一项总额可观的补偿方案。该方案的核心内容包括：以每股0.20美元的价格，获得总计16亿股的公司股份。此外，作为协议的一部分，这些成员还将获得相当于其总股份价值20%的或然价值权。这一安排旨在为特定股东群体提供额外的价值补偿与潜在收益保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169821140","title":"Liminatus Pharma LLC宣布计划启动新一代CD47阻断抗体Iba101的1期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1169821140","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169821140?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:09","pubTimestamp":1773749353,"startTime":"0","endTime":"0","summary":"生物制药公司Liminatus Pharma LLC近日公布了一项重要研发进展，其新一代CD47阻断抗体Iba101已正式提上临床开发日程。公司计划启动针对该候选药物的1期临床试验，旨在初步评估其在人体中的安全性、耐受性及药代动力学特征。\nCD47作为一种在多种癌细胞表面过度表达的“别吃我”信号蛋白，已成为肿瘤免疫治疗领域的热门靶点。Iba101作为新一代阻断抗体，旨在通过创新机制增强巨噬细胞对肿瘤细胞的吞噬作用，有望为癌症患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611077219","title":"Liminatus Pharma, Inc.盘中异动 早盘股价大涨6.87%报0.638美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611077219","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611077219?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:32","pubTimestamp":1770906740,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时32分，Liminatus Pharma, Inc.股票出现异动，股价快速上涨6.87%。截至发稿，该股报0.638美元/股，成交量81.8521万股，换手率3.02%，振幅6.43%。Liminatus Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Viking Therapeutics, Inc.、Lunai Bioworks Inc.、Tyra Biosciences, Inc.涨幅较大，Onconetix, Inc.、Quince Therapeutics, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为258.06%、79.21%、30.42%，振幅较大的相关个股有Cytomed Therapeutics Limited、Cue Biopharma, Inc.、Karyopharm Therapeutics Inc.，振幅分别为13.22%、9.33%、9.09%。Liminatus Pharma, Inc.公司简介：Liminatus Pharma Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223220a49ce86e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223220a49ce86e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LIMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154592636","title":"Liminatus Pharma LLC 将以发行400万股普通股换取持有者交回并注销805,377份认股权证","url":"https://stock-news.laohu8.com/highlight/detail?id=1154592636","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154592636?lang=zh_cn&edition=full","pubTime":"2026-02-10 04:05","pubTimestamp":1770667513,"startTime":"0","endTime":"0","summary":"Liminatus Pharma LLC 宣布了一项资本结构调整方案。根据协议，该公司将向特定权证持有者发行总计400万股普通股。作为交换，持有者需交回并注销其持有的805,377份认股权证。\n此项交易旨在优化公司的资本结构，并简化股权工具。通过以股份置换权证，公司可以巩固股权基础，并可能减少未来因权证行权导致的潜在股权稀释。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609532153","title":"Liminatus Pharma, Inc.盘中异动 股价大涨24.83%报1.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609532153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609532153?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:40","pubTimestamp":1770302421,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日22时40分，Liminatus Pharma, Inc.股票出现异动，股价大幅拉升24.83%。截至发稿，该股报1.79美元/股，成交量923.402万股，换手率34.12%，振幅27.97%。Liminatus Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.71%。其相关个股中，Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Fibrobiologics, Inc.涨幅较大，Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Propanc Biopharma, Inc.较为活跃，换手率分别为1339.54%、924.71%、190.65%，振幅较大的相关个股有Aim Immunotech Inc.、Bone Biologics Corp C/Wts 13/10/2026 、Liminatus Pharma, Inc.，振幅分别为37.91%、28.16%、27.97%。Liminatus Pharma, Inc.公司简介：Liminatus Pharma Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522402197a50dbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522402197a50dbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LIMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609390221","title":"Liminatus Pharma, Inc.盘中异动 股价大涨15.04%报1.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609390221","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609390221?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:31","pubTimestamp":1770215485,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日22时31分，Liminatus Pharma, Inc.股票出现波动，股价急速拉升15.04%。截至发稿，该股报1.23美元/股，成交量861.126万股，换手率31.82%，振幅14.90%。Liminatus Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.57%。其相关个股中，Liminatus Pharma, Inc.、Oncolytics Biotech Inc.、Xtl生物制药涨幅较大，Biodexa Pharmaceuticals Plc、Gri Bio, Inc.、Evogene Ltd.较为活跃，换手率分别为341.37%、180.51%、93.96%，振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Liminatus Pharma, Inc.、Bioatla, Inc.，振幅分别为18.20%、14.90%、14.07%。Liminatus Pharma, Inc.公司简介：Liminatus Pharma Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204223125a6d344d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204223125a6d344d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LIMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0712},{"period":"1month","weight":-0.1028},{"period":"3month","weight":-0.4981},{"period":"6month","weight":-0.8128},{"period":"1year","weight":-0.9836},{"period":"ytd","weight":-0.8311}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Liminatus Pharma, Inc.是一家特拉华州公司，成立于2022年11月23日。Liminatus是一家临床前阶段的生物制药公司，开发新型的免疫调节癌症疗法。公司候选IBA101，是一种人源化抗CD47单抗。下一代CD47检查点抑制剂的初步适应症预计为包括非小细胞肺癌在内的晚期实体癌患者。作为一家全球领先的生物制药公司，该公司的愿景是为癌症患者开发一系列广泛的变革性疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012085},{"month":2,"riseRate":0.8,"avgChangeRate":-0.095795},{"month":3,"riseRate":0.4,"avgChangeRate":-0.116654},{"month":4,"riseRate":0.6,"avgChangeRate":-0.021172},{"month":5,"riseRate":0.2,"avgChangeRate":-0.040756},{"month":6,"riseRate":0.5,"avgChangeRate":0.116229},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.090184},{"month":8,"riseRate":0.2,"avgChangeRate":-0.116647},{"month":9,"riseRate":0.4,"avgChangeRate":-0.076627},{"month":10,"riseRate":0.6,"avgChangeRate":-0.02675},{"month":11,"riseRate":0.4,"avgChangeRate":-0.052841},{"month":12,"riseRate":0.6,"avgChangeRate":-0.075377}],"exchange":"NASDAQ","name":"Liminatus Pharma LLC","nameEN":"Liminatus Pharma LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Liminatus Pharma LLC(LIMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Liminatus Pharma LLC(LIMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Liminatus Pharma LLC,LIMN,Liminatus Pharma LLC股票,Liminatus Pharma LLC股票老虎,Liminatus Pharma LLC股票老虎国际,Liminatus Pharma LLC行情,Liminatus Pharma LLC股票行情,Liminatus Pharma LLC股价,Liminatus Pharma LLC股市,Liminatus Pharma LLC股票价格,Liminatus Pharma LLC股票交易,Liminatus Pharma LLC股票购买,Liminatus Pharma LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Liminatus Pharma LLC(LIMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Liminatus Pharma LLC(LIMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}